Athenex (ATNX) PT Raised to $31 at RBC Capital; Bear Confirms Error
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Athenex (ATNX) Granted FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
June 24, 2019 7:07 AM EDTAthenex, Inc. (NASDAQ: ATNX) today announced that the U.S. Food and Drug Administration (FDA) has allowed the Companys Investigational New Drug (IND) application for the clinical investigation of PT01 (Pegtomarginase) for the treatment of patients with advanced malignancies. The allowance is contingent upon formal submission of agreed upon updates to the IND. Pegtomarginase is a biologic product candidate in Athenexs pipeline that is designed to provide a metabolic approach to the treatment of cancer through arginine deprivation therapy.
Pegtomarginase is a PEGylated genetically modified human arginase that targets cancer... More
